AstraZeneca announced that its new UK-based global research and development center and corporate headquarters will be located at the Cambridge Biomedical Campus on the southern outskirts of the city. By 2016, the new site will house a workforce of approximately 2,000.
As announced on 18 March 2013, the investment in a £330 million facility in Cambridge is part of the company’s move to create strategic global R&D centers in the UK, US, and Sweden to improve pipeline productivity.
The purpose-built site in Cambridge will bring together AstraZeneca’s small molecule and biologics research and development activity, opening up opportunities to exploit the promise of small and large molecule combinations. The Cambridge Biomedical Campus will be the new UK home for biologics research and protein engineering carried out by MedImmune, AstraZeneca’s biologics arm. MedImmune already employs around 500 people at Granta Park, to the south east of the city.
The new site will also become the company’s largest center for oncology research as well as hosting scientists focused on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases, and conditions of the central nervous system. Work carried out in Cambridge will include medicinal chemistry and high-throughput screening and the facility will accommodate a number of AstraZeneca’s pre-clinical research capabilities. Other global functions will join the research and development teams at the new facility and Cambridge will become AstraZeneca’s corporate headquarters.
Pascal Soriot, Chief Executive Officer of AstraZeneca said: “Cambridge competes on the global stage as a respected innovation hub for life sciences and our choice of site puts us at the heart of this important ecosystem, providing valuable collaboration opportunities. Moving to the Cambridge Biomedical Campus means our people will be able to rub shoulders with some of the world’s best scientists and clinicians carrying out some of the world’s leading research—that’s a really exciting prospect. We hope that our move will contribute to the growing success of Cambridge.
David Willetts MP, Minister for Universities and Science at the Department for Business, Innovation and Skills, said: “AstraZeneca’s investment is excellent news for the UK life sciences industry. It strengthens our global competitiveness and supports our aim of making the UK the best place in the world for the discovery and commercialization of medical innovations. These are key themes of the Government's life sciences strategy."
Professor Sir Leszek Borysiewicz FRS, Vice-Chancellor of the University of Cambridge, said: “I am delighted with AstraZeneca’s choice. It is a measure of the world-class environment that Cambridge offers to knowledge-based industries and it reflects AstraZeneca’s commitment to making new discoveries. Over 1,500 companies in the Cambridge cluster of high-tech industries have found that proximity–to the University, to our NHS partners, and to each other–enables productive relationships and stimulates competition. As a global player, AstraZeneca will add tremendously to that environment and we look forward to the creative collaborations that will surely follow.”